Page 38 - Read Online

Soren et al. Cancer Drug Resist 2020;3:18-25 I http://dx.doi.org/10.20517/cdr.2019.106 Page 25

30. Tesauro C, Morozzo della Rocca B, Ottaviani A, Coletta A, Zuccaro L, et al. Molecular mechanism of the camptothecin resistance of
Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico. Mol Cancer 2013;12:100.
31. D’Annessa I, Coletta A, Sutthibutpong T, Mitchell J, Chillemi G, et al. Simulations of DNA topoisomerase 1B bound to supercoiled
DNA reveal changes in the flexibility pattern of the enzyme and a secondary protein-DNA binding site. Nucleic Acids Res
2014;42:9304-12.
32. Sari L, Andricioaei I. Rotation of DNA around intact strand in human topoisomerase I implies distinct mechanisms for positive and
negative supercoil relaxation. Nucleic Acids Res 2005;33:6621-34.
33. Punchihewa C, Dai J, Carver M, Yang D. Human topoisomerase I C-terminal domain fragment containing the active site tyrosine is a
molten globule: implication for the formation of competent productive complex. J Struct Biol 2007;159:111-21.
34. Cretaio E, Pattarello L, Fontebasso Y, Banedetti P, Losasso C. Human DNA topoisomerase IB: structure and functions. Ital J Biochem
2007;56:91-102.
35. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al. UCSF Chimera - a visualization system for exploratory
research and analysis. J Comput Chem 2004;25:1605-12.
36. Tesauro C, Fiorani P, D’Annessa I, Chillemi G, Turchi G, et al. Erybraedin C, a natural compound from the plant Bituminaria
bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I. Biochem J 2010;425:531-9.
37. Arnò B, Coletta A, Tesauro C, Zuccaro L, Fiorani P, et al. A small organic compound enhances the religation reaction of human
topoisomerase I and identifies crucial elements for the religation mechanism. Biosci Rep 2013;33:e00025.
38. Wu N, Wu XW, Agama K, Pommier Y, Du J, et al. A novel DNA topoisomerase I inhibitor with different mechanism from
camptothecin induces G2/M phase cell cycle arrest to K562 cells. Biochemistry 2010;49:10131-6.
39. Ganguly A, Das B, Roy A, Sen N, Dasgupta SB, et al. Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen
species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process
of cell death. Cancer Res 2007;67:11848-58.
40. Beretta GL, Gatti L, Perego P, Zaffaroni N. Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-
damaging drug. Curr Med Chem 2013;20:1541-65.
41. Li F, Jiang T, Li Q, Ling X. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism
of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am J Cancer Res
2017;7:2350-94.
42. Pizzolato JF, Saltz LB. Irinotecan (Campto®) in the treatment of pancreatic cancer. Expert Rev Anticancer Ther 2003;3:587-93.
43. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-42.
44. Horwitz MS, Horwitz SB. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. Biochem Biophys
Res Commun 1971;45:723-7.
45. Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, et al. Characterization of a novel topoisomerase I mutation from a
camptothecin-resistant human prostate cancer cell line. Cancer Res 2001;61:1964-9.
46. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109:2894-902.
47. Lisby M, Olesen JR, Skouboe C, Krogh BO, Straub T, et al. Residues within the N-terminal domain of human topoisomerase I play a
direct role in relaxation. J Biol Chem 2001;276:20220-7.
48. Fiorani P, Chillemi G, Losasso C, Castelli S, Desideri A. The different cleavage DNA sequence specificity explains the camptothecin
resistance of the human topoisomerase I Glu418Lys mutant. Nucleic Acids Res 2006;34:5093-100.
49. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, et al. Mechanisms of camptothecin resistance by human topoisomerase I
mutations. J Mol Biol 2004;339:773-84.
50. Benedetti P, Fiorani P, Capuani L, Wang JC. Camptothecin resistance from a single mutation changing glycine 363 of human DNA
topoisomerase I to cysteine. Cancer Res 1993;53:4343-8.
51. Fiorani P, Amatruda JF, Silvestri A, Butler RH, Bjornsti MA, et al. Domain interactions affecting human DNA topoisomerase I
catalysis and camptothecin sensitivity. Mol Pharmacol 1999;56:1105-15.
52. D’Annessa I, Tesauro C, Wang Z, Arnò B, Zuccaro L, et al. The human topoisomerase 1B Arg634Ala mutation results in camptothecin
resistance and loss of inter-domain motion correlation. Biochim Biophys Acta 2013;1834:2712-21.
53. D’Annessa I, Tesauro C, Fiorani P, Chillemi G, Castelli S, et al. Role of flexibility in protein-DNA-drug recognition: the case of
Asp677Gly-Val703Ile topoisomerase mutant hypersensitive to camptothecin. J Amino Acids 2012;2012:206083.
54. Arnò B, D’Annessa I, Tesauro C, Zuccaro L, Ottaviani A, et al. Replacement of the human topoisomerase linker domain with the
plasmodial counterpart renders the enzyme camptothecin resistant. PLoS One 2013;8:e68404.
55. Wright CM, Van Der Merwe M, DeBrot AH, Bjornsti MA. DNA topoisomerase I domain interactions impact enzyme activity and
sensitivity to camptothecin. J Biol Chem 2015;290:12068-78.
56. Losasso C, Cretaio E, Fiorani P, D’Annessa I, Chillemi G, et al. A single mutation in the 729 residue modulates human DNA
topoisomerase IB DNA binding and drug resistance. Nucleic Acids Res 2008;36:5635-44.
57. Pourquier P, Pommier Y. Topoisomerase I-mediated DNA damage. Adv Cancer Res 2001;80:189-216.
58. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human
leukemia cell line resistant to camptothecin. Cancer Res 1995;55:1339-46.